Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α

Ute Ströher, Antonino DiCaro, Yan Li, James E. Strong, Fred Aoki, Frank Plummer, Steven M. Jones, Heinz Feldmann

Research output: Contribution to journalArticlepeer-review


Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)-α in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN-α showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN-α might be justified to determine a beneficial effect on the outcome of SARS.

Original languageEnglish
Pages (from-to)1164-1167
Number of pages4
JournalJournal of Infectious Diseases
Issue number7
Publication statusPublished - Apr 1 2004

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology


Dive into the research topics of 'Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α'. Together they form a unique fingerprint.

Cite this